Induced Pluripotent Stem (iPS) Cells in Medicine and Research

Induced pluripotent stem cells have led to unprecedented opportunities in the pharmaceutical industry, but also in clinical and basic research. Some of the fields where induced pluripotent stem cells have created ripples are discussed below.

Production of induced pluripotent stem cells.metamorworks | Shutterstock

Cell transplantation therapy

Since their discovery in 1998, embryonic stem cells were thought to the key to treat intractable diseases, including Parkinson’s disease and spinal cord injury. However, embryonic stem cells have been riddled with ethical concerns regarding their use and scientific concerns of post-transplantation rejection. In 2007, a proof-of-concept study was reported where induced pluripotent cells were used for the mouse model of sickle cell anemia.

This specific gene was corrected by using homologous recombination in the mutant iPSC cell line and subsequently transplanted into mutant mice, which led to disease cure. A major advantage of iPSC use is that donor candidates can be easily accessed. However, before creating clinical-grade iPSC clones from a donor, their health conditions and type of human leukocyte antigen (HLA) should be known. Cord blood and peripheral blood are also good sources for iPSCs.

Masayo Takahashi - 2015 Winner of Ogawa-Yamanaka Stem Cell Prize

Disease modeling and drug screening

Disease modeling and screening for drugs also constitute important applications of iPSCs. While animal models have made a tremendous contribution to our understanding of disease mechanisms, they have their limitations.

For example, several drugs showed therapeutic effects in rodent models of amyotrophic lateral sclerosis (ALS); however, all of them were ineffective in human patients. This indicates the importance of using animal cells. Currently, several patient-specific iPSC lines have been set-up and used as a model system for diseases, which will also enable the study of rare diseases.

Below is a list of other diseases in which fibroblasts have been used as source cells and lentiviral integration has been used for the generation of iPS cells.

  • Huntington disease (HD)
  • ALS or Lou Gehrig's disease
  • Friedreich's ataxia (FRDA)
  • Shwachman-Bodian-Diamond syndrome (SBDS)
  • Gaucher's type III
  • Becker type muscular dystrophy (BMD)
  • Downs syndrome/trisomy 21
  • Familial dysautonomia (FD) or Riley-Day syndrome
  • Spinal muscular atrophy
  • Type 1 diabetes mellitus (DM)

Basic sciences

Reprogramming technologies assist in understanding the link between epigenetic factors and cellular identity. Reprogramming also helps to assess how transcriptional and epigenetic changes are involved in cancer development.

The latter is due to the fact that reprogramming shares common events with carcinogenesis - for example, mesenchymal-epithelial transition and the involvement of c-Myc and p53. Also, reprogrammed somatic cells can help in investigating the causes of aging and the accumulation of genetic errors over time.

Colony of stem cellsFunTravel | Shutterstock

Why are there concerns over the safety of iPS cells?

In 2007, Okita and colleagues generated induced pluripotent cell lines from mouse embryonic fibroblasts which showed embryonic stem cell-like gene expression and methylation patterns of DNA. These cell lines had similar pluripotency when compared to the embryonic stem cells; however, 20% of these chimeric mice also developed tumors due to reactivation of the c-Myc transgene.

This led to the suspicion that while induced pluripotent cells had identical properties in terms of stemness, they may not be as safe as embryonic stem cells; furthermore, the involvement of c-Myc could result in an increased risk of tumor development.  

Nakagawa and colleagues tried to resolve this concern when they successfully generated induced pluripotent cells using Sox2, Klf4, and Oct3/4. The lack of c-Myc could significantly reduce the tumorigenicity risk. However, the non-usage of c-Myc also has its disadvantages, as it reduces the efficiency of induced pluripotent stem cells.

A study in 2011 showed that iPS cells could provoke an immune response when injected in mice. However, when Masumi Abe (a scientist at the National Institute of Radiological Sciences in Japan) took iPS and embryonic stem cells from mice and re-injected them, there were no differences in the immune response of the two groups, suggesting that the fears of immune response due to induced pluripotent cells may have been overestimated.

In another study, conducted at Yale University in 2012, researchers found that the reprogramming process led to fewer mutations than what was previously thought. Thus, induced pluripotent cells are a promising opportunity for therapeutic applications; however, further research and assessment is required to review all the epigenetic and genetic changes observed in induced pluripotent stem cells to determine the exact risks of this procedure.

Stem cell safety test


Further Reading

Last Updated: Jul 17, 2019

Dr. Surat P

Written by

Dr. Surat P

Dr. Surat graduated with a Ph.D. in Cell Biology and Mechanobiology from the Tata Institute of Fundamental Research (Mumbai, India) in 2016. Prior to her Ph.D., Surat studied for a Bachelor of Science (B.Sc.) degree in Zoology, during which she was the recipient of an Indian Academy of Sciences Summer Fellowship to study the proteins involved in AIDs. She produces feature articles on a wide range of topics, such as medical ethics, data manipulation, pseudoscience and superstition, education, and human evolution. She is passionate about science communication and writes articles covering all areas of the life sciences.  


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    P, Surat. (2019, July 17). Induced Pluripotent Stem (iPS) Cells in Medicine and Research. News-Medical. Retrieved on June 17, 2024 from

  • MLA

    P, Surat. "Induced Pluripotent Stem (iPS) Cells in Medicine and Research". News-Medical. 17 June 2024. <>.

  • Chicago

    P, Surat. "Induced Pluripotent Stem (iPS) Cells in Medicine and Research". News-Medical. (accessed June 17, 2024).

  • Harvard

    P, Surat. 2019. Induced Pluripotent Stem (iPS) Cells in Medicine and Research. News-Medical, viewed 17 June 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Stem cell models unlock secrets of early human embryo development